U.S. Markets close in 21 mins
  • S&P 500

    4,516.32
    -60.78 (-1.33%)
     
  • Dow 30

    34,435.22
    -204.57 (-0.59%)
     
  • Nasdaq

    15,002.87
    -378.45 (-2.46%)
     
  • Russell 2000

    2,153.46
    -52.87 (-2.40%)
     
  • Crude Oil

    66.08
    -0.42 (-0.63%)
     
  • Gold

    1,785.70
    +23.00 (+1.30%)
     
  • Silver

    22.45
    +0.17 (+0.76%)
     
  • EUR/USD

    1.1310
    +0.0004 (+0.0339%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    31.89
    +3.94 (+14.10%)
     
  • GBP/USD

    1.3231
    -0.0071 (-0.5345%)
     
  • USD/JPY

    112.7680
    -0.4410 (-0.3895%)
     
  • BTC-USD

    52,840.40
    -4,289.52 (-7.51%)
     
  • CMC Crypto 200

    1,344.64
    -97.12 (-6.74%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day. The panel entitled “The more we learn the less we know about DMD—From micro-dystrophin, to morpholinos, and small molecules” will be held on Thursday, April 1, 2021 from 9:00 a.m. - 9:50 a.m. Eastern Time.

A live webcast of the presentation will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com